Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPRO MED SYSTEMS, INC.

(KRMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Repro-Med Systems, Inc. : Repro Med Systems, Inc. Qualifies To Trade On OTCQX Market

09/18/2015 | 07:32am EDT

CHESTER, NY / ACCESSWIRE / September 18, 2015 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR), a manufacturer of medical devices for the ambulatory (home and institution) infusion market, has qualified to trade on the OTCQX(R) Best Market. Repro Med begins trading today on OTCQX under the symbol "REPR." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Image: https://www.accesswire.com/uploads/princeton%20research1.jpg

R. Cromwell Coulson, President and CEO of OTC Markets Group, said, "We are pleased to welcome Repro Med to the family of established, global and growth companies on our OTCQX market," "OTCQX provides a transparent public trading market for growing companies like Repro Med that are committed to maintaining high-quality financial and operating standards. We look forward to supporting Repro Med in its continued growth as a publicly-traded company."

In addition to meeting high financial and disclosure standards, OTCQX U.S. companies must be sponsored by an approved third-party investment bank or law firm called a Designated Advisor For Disclosure ("DAD"). Salon Marrow Dyckman Newman & Broudy LLP serves as Repro Med's DAD on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.

Andrew Sealfon, President of RMS, commented, "Our focus on building our core business is bearing gratifying results in building value for our shareholders. Qualifying for trading on OTCQX is an important step in fulfilling our commitments to transparency and compliance. It is also an important foundation for executing our long term strategy for product line expansion and profitable sales growth."

About Repro Med Systems, Inc.

Repro Med designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications for domestic and international markets.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes", "belief", "expects", "intends", "anticipates", "will", or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.

For more information please call:

Mike King
702-650-3000
Princeton Research

SOURCE: Repro-Med Systems, Inc.


ę Accesswire 2015
All news about REPRO MED SYSTEMS, INC.
05/25SHAREHODLER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
05/24THE LAW OFFICES OF FRANK R. CRUZá : Reminds Investors of Looming Deadline in the..
BU
05/20REPRO MEDá : Last Few Days to Actively Participate Repro-Med Systems, Inc. (KRMD..
BU
05/19REPRO MED SYSTEMS INCá : Submission of Matters to a Vote of Security Holders (fo..
AQ
05/19REPRO MEDá : 2021 Annual Meeting of Shareholders Presentation
PU
05/18SHAREHODLER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
05/14REPRO MEDá : KORU MEDICAL SYSTEMS ANNOUNCES 2021 FIRST QUARTER FINANCIAL RESULTS..
PU
05/12REPRO MEDá : Part i - item 2. management's discussion and analysis of financial ..
AQ
05/12REPRO MED SYSTEMS INCá : Results of Operations and Financial Condition, Financia..
AQ
05/12REPRO MEDá : Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q1 Revenue $5.4M, ..
MT
More news
Financials (USD)
Sales 2021 22,5 M - -
Net income 2021 -3,41 M - -
Net Debt 2021 - - -
P/E ratio 2021 -52,8x
Yield 2021 -
Capitalization 180 M 180 M -
Capi. / Sales 2021 8,00x
Capi. / Sales 2022 6,79x
Nbr of Employees -
Free-Float 82,3%
Chart REPRO MED SYSTEMS, INC.
Duration : Period :
Repro Med Systems, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPRO MED SYSTEMS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 4,05 $
Average target price 5,17 $
Spread / Average Target 27,6%
EPS Revisions
Managers and Directors
NameTitle
Linda M. Tharby President & Chief Executive Officer
Karen A. Fisher Chief Financial Officer, Secretary & Treasurer
R. John Fletcher Chairman
Brian Schiller Vice President-Medical Affairs
Manuel Marques Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
REPRO MED SYSTEMS, INC.-31.40%184
ABBOTT LABORATORIES1.34%197 156
MEDTRONIC PLC8.19%170 503
BECTON, DICKINSON AND COMPANY-3.96%69 890
HOYA CORPORATION4.06%49 121
ALIGN TECHNOLOGY, INC.13.16%47 855